Alzheimer's Disease Diagnosis and Plasma Phospho‐tau217 (ADAPT) Stage 1
In both cohorts the accuracy of Lumipulse plasma p-tau217 in those assigned either high or low values exceeded 90%, and NPV was greater than for ALZpath p-tau217. The validated Lumipulse cut-points will be implemented as part of a randomized controlled trial of result disclosure in community memory clinics.
Authors
- Melanie Hart (ORCID: https://orcid.org/0000-0002-7396-1916)
- Ashvini Keshavan (ORCID: https://orcid.org/0000-0003-1043-5721)
- Michael Peter Lunn (ORCID: https://orcid.org/0000-0003-3174-6027)
- Katharine Wiltshire
- Malhotra Paresh
- Jonathan M Schott
Institutions
- Queen Mary University of London (GB)
- UK Dementia Research Institute (GB)
- MRC Prion Unit (GB)
- NIHR Queen Square Dementia Biomedical Research Unit (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100166
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00